Review Article

Inhibitor of Differentiation-3 and Estrogenic Endocrine Disruptors: Implications for Susceptibility to Obesity and Metabolic Disorders

Mayur Doke, Vincent Avecilla, and Quentin Felty

Department of Environmental & Occupational Health, Florida International University, Miami, FL, USA

Correspondence should be addressed to Quentin Felty; feltyq@fiu.edu

Received 5 May 2017; Revised 7 November 2017; Accepted 23 November 2017; Published 8 January 2018

Copyright © 2018 Mayur Doke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The rising global incidence of obesity cannot be fully explained within the context of traditional risk factors such as an unhealthy diet, physical inactivity, aging, or genetics. Adipose tissue is an endocrine as well as a metabolic organ that may be susceptible to disruption by environmental estrogenic chemicals. Since some of the endocrine disruptors are lipophilic chemicals with long half-lives, they tend to bioaccumulate in the adipose tissue of exposed populations. Elevated exposure to these chemicals may predispose susceptible individuals to weight gain by increasing the number and size of fat cells. Genetic studies have demonstrated that the transcriptional regulator inhibitor of differentiation-3 (ID3) promotes high fat diet-induced obesity in vivo. We have shown previously that PCB153 and natural estrogen 17β-estradiol increase ID3 expression. Based on our findings, we postulate that ID3 is a molecular target of estrogenic endocrine disruptors (EEDs) in the adipose tissue and a better understanding of this relationship may help to explain how EEDs can lead to the transcriptional programming of deviant fat cells. This review will discuss the current understanding of ID3 in excess fat accumulation and the potential for EEDs to influence susceptibility to obesity or metabolic disorders via ID3 signaling.

1. Introduction

Obesity is considered to be one of the most significant public health challenges of the 21st century [1]. Population based studies have shown the association between obesity and metabolic disorders which include diabetes, insulin resistance, coronary heart disease, and fatty liver disease [2–5]. Obesity is a medical condition defined as the excess accumulation of body fat. The World Health Organization (WHO) stated in a previous report that approximately 650 million people were obese, 18 years and older in the world during 2016 [6]. The economic impact of obesity on health care costs has been estimated to be more than 200 billion dollars in the US [7]. The European Union (EU) has expected the associated costs of obesity and diabetes to be over 18 billion euros per year from exposure to endocrine disrupting chemicals [8]. Currently, there is an unmet need to understand how endocrine disrupting chemicals contribute to susceptibility to obesity and metabolic disorders.

Estrogen is a class of hormones with a myriad of functions including the regulation of adipose tissue and metabolism [9]. Adipose tissue is a complex metabolic, endocrine organ. The relative contribution of adipose tissue to steroid production is significant with adipose tissue producing up to 100% of circulating estrogen in postmenopausal women and 50% circulating testosterone in premenopausal women [10, 11]. Aromatase enzyme is expressed in preadipocytes and adipose tissue stromal cells. Aromatase catalyzes the conversion of androgens (androstenedione and testosterone) to estrogen (estrone and estradiol) in the endoplasmic reticulum [12–15]. Both estrogen receptor (ER) subtypes ERα and ERβ are found in adipose cells [16, 17]. 17β-Estradiol (E2) signaling occurs through both genomic (nuclear) and nongenomic (extra-nuclear) pathways [18, 19]. Nuclear estrogen receptors consist of ERα and ERβ, while membrane estrogen receptors (mERs: GPER, GPR30, ER-X, and Gq-mER) are mostly G protein-coupled receptors [20–26]. Since the adipose tissue is an endocrine organ, it may be susceptible to EEDs. Endocrine
disruptors are chemicals that alter hormone production or function including phytoestrogens, heavy metals, and anthropogenic chemicals. More specifically, EEDs include compounds such as genistein, arsenic, DES, PCBs, phthalates, and bisphenol A (BPA). Relative binding affinities of orphan, para-DDE, hydroxylated PCB, BPA, and DES have been shown to be significantly weaker than E2 in binding to nuclear ERs and mERs like GPR30 [27–31]. Moreover, EEDs have been shown to mimic estrogenic activity and interfere with the endocrine system through these receptor signaling pathways [32–34]. A recent study of offspring from pregnant women exposed to DES showed an association with obesity [36]. Early-life exposure to DES was shown to increase obesity in mice at 4–6 months of age compared to control mice [36]. Thus, elevated exposure to EEDs is of concern because they may predispose susceptible individuals to weight gain by increasing the number and size of fat cells. This review is focused on linking the obesogenic effects of EEDs to ID3 signaling leading to increased fat accumulation or obesity.

2. Transcription Regulator ID3

The molecular factors that contribute to the development of excess body fat in response to endocrine disruption have yet to be fully elucidated. Genetic studies have demonstrated that the transcriptional regulator ID3 promotes high fat diet-induced obesity in vivo. The ID (inhibitor of differentiation) family of small proteins consists of four genes (ID1–ID4). ID1 and ID3 have been shown to regulate cell growth, self-renewal, senescence, angiogenesis, and neurogenesis [37–42]. Depending on the cellular context, ID1 and ID3 have been shown to exhibit overlapping functions as dual gene knockout combinations have demonstrated redundancy [43]. ID1 and ID3 have been shown to be coexpressed in early development of the cell cycle progression, angiogenesis, and neurogenesis in the mouse model [40–42]. Amongst PCB congeners, PCB153 has been found to be one of the largest contributors to total PCB body burden in humans and a diet-dependent obesogen in the experimental model [44, 45]. We have previously demonstrated that PCB153 modulates ID3 expression and phosphorylation [46]. ID3 is highly expressed in the embryonic tissue and highly proliferating and undifferentiated adult cells [43]. We and others have shown that PCB153 increases oxidative stress or reactive oxygen species (ROS) that mediate ID3 expression [47, 48]. Exposure to estrogenic chemicals has been shown to increase ROS in the nucleus in which they modify the surrounding DNA necessary for transcriptional activation of cell growth genes [49–51]. In other words, ROS that we have already shown to be induced by treatment with PCB153 may be involved in ID3 mediated transcription regulation. EEDs have been shown to increase ROS production in adipocytes. Di-(2-ethylhexyl)phthalate (DEHP) increased ROS in rat adipocytes [52]. The plastic chemical BPA which has been linked to obesity in both human and animals studies was demonstrated to increase ROS levels in mesenchymal stem cells involved in the process of adipogenesis [53, 54]. Mitochondria are a major source of ROS production in mammalian cells [55]. Although other endogenous ROS sources besides mitochondria such as NADPH oxidase exist, we have shown that estrogenic chemicals increase mitochondrial ROS [56]. Furthermore, the presence of ERα and ERβ in mitochondria may potentially be targets of EEDs contributing to oxidative stress [57–59]. Although there is evidence linking EEDs exposure to increased mitochondrial (mt) ROS, it is unclear whether it is responsible for redox-sensitive phosphorylation of ID3 upon exposure to PCB153.

Transcriptional regulation by ID3 ultimately functions to increase cell proliferation and preserve multipotency. ID3 mediated gene regulation governing these processes in adipocytes and stem/progenitor fat cells provides a possible explanation for how ID3 promotes high fat diet-induced obesity in the experimental model [60]. ID3 protein-protein interactions occur via the helix loop helix (HLH) motif. ID3 protein interactions block the DNA binding activity of basic HLH (bHLH) transcription factors encoded by the genes TCF3, TCF4, and TCF12. TCF3 gene encodes for E12, E47 proteins. TCF4 gene encodes for E-2-2, and TCF12 gene encodes for HEB proteins in humans [61]. E12, E47, E2-2, and HEB proteins are a class I bHLH proteins which consists of basic DNA binding domain. These E-proteins specifically recognize and bind to Ephrussi-box (E-box) sequences (CANNTG) on the DNA [62, 63]. ID3 has been most often reported to interact with proteins encoded by TCF3 gene [39]. ID3 protein-protein interactions can regulate transcription by E-proteins preventing their binding and subsequent activation of target gene promoters [39]. ID3 has frequently been described throughout the literature as an inhibitor of gene expression. For example, ID3 promotes cells to pass through cell cycle checkpoints by inhibiting the expression of cell cycle inhibitor gene p21Cip1 (Figure 1) [64]. However, ID3 can also act as a positive transcriptional regulator depending on the cellular context. E-proteins suppress the expression of embryonic genes OCT4, SOX2, and NANOG leading to cell differentiation [65]. As shown in Figure 1, ID3 can increase the expression of these embryonic genes by repressing TCF3. We have demonstrated that ectopic overexpression of ID3 increased OCT4 and SOX2 expression and resulted in a cell population positive for molecular stem cell markers CD133+ VEGFR3+ CD34+ [66]. Based on these findings, ID3 can maintain undifferentiated cells by increasing the expression of embryonic pluripotency factors via repression of TCF3. Since ID3 is a transcription regulator of genes involved in both cell proliferation and stemness, EEDs may facilitate the uncontrolled proliferation of adipocytes through ID3 contributing to obesity or metabolic disorders.

Exposure to EEDs may also exert their negative health effects by altering epigenetic marks including DNA methylation and histone acetylation ultimately influencing gene expression in adipose tissue cells. Epigenetic transgenerational inheritance of obesity has been demonstrated in animals exposed to EEDs: BPA and phthalates [67]. Early-life exposures to EEDs like DES and PCB153 are known to alter DNA methyltransferase activity [68]. Since altered DNA methylation have been found in PCB153 exposed adipocytes [69], it is biologically plausible that chromatin modifications
including acetylation/deacetylation of histones are another way for ID3 to regulate transcription. ID proteins have been shown to promote acetylation and transcriptional activity by recruiting histone acetyltransferase (HATs): (i) CREB-binding protein (CBP), (ii) p300 (EIA binding protein p300), and/or P300/CREB-associated factor (PCAF) to the chromatin [70]. Moreover, ID proteins interact with another chromatin modifying the protein, ZRF1 [71]. These evidences suggest that ID3 may regulate transcription through interactions with both transcription factors and chromatin modifying proteins. Although a molecular risk factor for obesity from exposure to EEDs is not known, we propose that ID3’s demonstrated involvement in HFD-induced obesity coupled with its functional role in transcription regulation of cell proliferation and stemness makes it a likely candidate for environmental disruption by EEDs.

3. Role of ID3 in Adipose Tissue

ID3 is expressed during embryonic development but declines throughout the maturation of the embryo [41]. Multipotency of adipocyte progenitor cells has been shown to be maintained by ectopic expression of ID3 [72]. Two types of adipose tissue in the body consist of white adipose tissue (WAT) and brown adipose tissue (BAT) [73]. The storage of excess energy in the form of triglycerides occurs in WAT. Exposure to a HFD or excessive energy intake can increase total body WAT by the accumulation of triglycerides that may lead to obesity through chronic exposure [74]. Several studies indicate a novel role for ID3 as a regulator of obesity. HFD-induced obesity was shown to be reduced in ID3−/− knockout (ID3 KO) compared to wild-type mice [75]. Exposure to a HFD showed increased ID3 expression in the expanded visceral WAT of only wild-type mice. Hence, ID3 KO prevented the observed increase in obesity from exposure to the HFD. ID3 KO mice had a significant reduction in VEGFA protein. The decrease of VEGFA was attributed to repression of its gene promoter due to the loss of ID3 in knockout mice. This study concluded that the loss of ID3 prevented HFD-induced obesity via inhibiting VEGFA expression and adipose tissue angiogenesis necessary to support the expansion of visceral fat. Moreover, recently researchers have demonstrated in a mouse model that ID1 protein, which is also a member of ID protein family, suppresses peroxisome proliferator-activated receptor γ coactivator 1a (PGC1α) which controls BAT-mediated thermogenesis and stimulates energy storage in adipocytes. Eventually, ID1 promotes obesity [76]. Our investigations of PCB153 exposed endothelial cells demonstrated that redox-sensitive ID3 signaling contributes neo-vascularization and vascular sphere formation [46]. Based on these evidences, we propose that the increase in fat cells from exposure to EEDs depends on ID3 mediated increase in blood vessels needed for the growth of fat tissue (Figure 2) [77].

Besides supporting an increase in blood supply to the fat tissue, ID3 may directly impact transcriptional programming of fat stem cells exposed to EEDs. For instance, the HFD-induced proliferation of fat stem cells was shown to be significantly inhibited in Id3 KO mice [60]. Since ID3 is important in the maintenance of multipotency, environmental disruption from exposure to EEDs may increase self-renewal of fat stem cells. The abundance of fat stem cells coupled with ID3 mediated proliferation may in turn lead to fat accumulation. Genetic knockout of cyclin-dependent kinase inhibitor p21Cip1 produces adipocyte hyperplasia and obesity in mice [78]. Consistent with this study, HFD significantly increased ID3 expression and decreased p21Cip1 mRNA in adipocyte progenitors [60]. Hence, Id3 KO mice may be protected from HFD-induced obesity due to the absence of adipocyte progenitor cells and/or high levels of p21Cip1. Together these evidences implicate ID3 as a molecular risk factor of obesity susceptible to environmental disruption especially to EEDs that accumulate in the fat tissue.
4. Role of ID3 in Inflammation

The inflammatory process across multiple organ systems has been implicated in the development of obesity and metabolic disorders. For example, insulin resistance and systemic inflammation result from complex interactions between the vasculature, adipose tissue, and immune cells [79, 80]. As described previously, ID3 is essential for vasculogenesis as well as the self-renewal of fat cells. However, its role in inflammation brings additional complexity to its role in disease pathogenesis. Inflammatory factors produced during obesity are a major pathway for developing metabolic complications. The induction of cytokines has been observed in population studies of obesity and/or metabolic syndrome (MetS). Several lines of evidence suggest that ID3 mediated inflammation may contribute to obesity through an imbalance in pro- and anti-inflammatory factors secreted by fat cells. Dysregulated expressions of adipokines have been observed in Id3 KO mice [81]. Adiponectin is a known adipokine that is one of the proinflammatory factors secreted by adipocytes and implicated in the development of obesity and metabolic disorders as described in the following studies. Low circulating levels of adiponectin have been linked to several components of the metabolic syndrome like intra-abdominal body fat distribution, hyperlipidemia, low high-density lipoprotein (HDL) levels, and insulin resistance/type 2 diabetes [81]. Adiponectin gene expression [82] and circulating adiponectin levels [83] are lower in patients with type 2 diabetes than in nondiabetic individuals. Population studies have shown that circulating adiponectin concentrations are reduced in obese individual [82–84]. In a cross-sectional study of men and women who were obese and lean, the negative relationship between plasma adiponectin and visceral fat (measured by computed tomography scan) was significantly stronger than that with subcutaneous fat [85]. Consistent with the observed association of low adiponectin in obesity and metabolic disorders, ID3 was found to suppress the transcription of adiponectin in adipocytes [81].

Interleukins are also potent mediators of the inflammatory response in immune and vascular cells. ID3 is known to regulate the production of IL-5, IL-6, IL-8, and IL-10 which have been observed in population studies of obesity and/or MetS [60, 86, 87]. Monocyte chemoattractant protein-1 (MCP-1) regulates inflammation in visceral adipose tissue and is increased in both obese mice and humans [60, 88].
Decrease in Adiponectin levels

MCP1

Recruitment of Macrophage

Blood vessels

Adipocyte proliferation

Adiponectin

Expression of MCP-1 was shown to be mediated by ID3 in fat stem cells, and MCP-1 promoted the recruitment of macrophages to the adipose tissue [60]. MCP-1 transgenic mice increased macrophage proliferation and induced expression of adipokines such as tumor necrosis factor-\(\alpha\) and interleukin-6 in adipocytes [89, 90]. Furthermore, pretreatment adipocytes with adiponectin significantly reduced expression of MCP-1 when exposed to lipopolysaccharides [91]. This demonstrates the inverse relationship between adiponectin level and MCP-1 expression. Based on this evidence, dysregulation of adipose tissue inflammation via ID3 may potentially be susceptible to exposure by EEDs. Repression of adiponectin, as well as activation of MCP-1 expression by EEDs, may create an imbalance of adipose tissue inflammatory factors. Individuals exposed to EEDs may be susceptible to ID3 mediated inflammation from macrophage recruitment via MCP-1 as well as loss of anti-inflammatory adipokine adiponectin [92]. The contribution of ID3 to vasculogenesis, energy metabolism, and the immune system make it a unique molecular factor to study in obesity because it cuts across these complex organ systems. Based on these studies, we have illustrated potential mechanisms that EEDs may share with HFD-induced obesity via ID3 control of adipose inflammation shown in Figure 3.

5. Role of Estrogen in Obesity

Although EEDs such as DES have been shown to be detrimental to an experimental model of obesity, the meaning of these studies becomes even more complex from studies of the natural estrogen, E2. Estrogen is essential in the regulation of metabolism and regional distribution of adipose tissue [93, 94]. The presence of ER\(\alpha\) and ER\(\beta\) in adipocytes established the initial link between estrogen levels and adipose cell function [95]. Population based studies have shown that ER\(\alpha\) expression was reduced in adipocytes from obese compared to normal weight females [96]. Adipose cells also constitute a significant fraction of total estrogen synthesis in males and postmenopausal females [97]. It has been shown that a mutation in the aromatase gene results in estrogen deprivation and fat accumulation in men [98]. In support of the protective effect of E2 in obesity, HFD fed mice exposed to E2 showed less adipogenesis [99]. E2 treatment decreased expression of lipogenic genes such as SREBP-1c (Sterol Regulatory Element Binding Protein 1c) and LXR-\(\alpha\) (Liver X Receptor \(\alpha\)), a positive regulator of SREBP-1c in adipose tissue [100]. Essentially, SREBP-1c can promote the expression of lipogenic genes such as FAS and acetyl-CoA carboxylase (ACC-1) [101]. However, by lowering the expression of SREBP-1c, E2 control the adipose cells differentiation. Estrogen and metabolic hormones like leptin, insulin, and adiponectin are
interlinked through hypothalamic GnRH neuronal network. ERα localizes along with leptin receptors in the hypothalamic region of CNS [102, 103]. Recently, it has been shown that specific silencing of ERα in hypothalamus results in increased food intake and a decline in energy expenditure resulting in development obesity via cholecystokinin signaling [104]. Peripheral effects are exerted directly on adipose tissue and include effects on thermogenesis and lipid synthesis through ERα [98]. Moreover, estrogen regulates the secretion and circulating levels of leptin in blood through local production of estrogen by adipocytes. Although the role of E2 is beneficial with respect to suppressing the accumulation of fat cells, EEDs could disrupt estrogen signaling pathways [105, 106]. Therefore, the involvement of EEDs in interfering estrogen signaling cannot be ignored.

6. Estrogenic Endocrine Disrupting Chemicals and Obesity

Many studies have discussed the effects of EEDs on reproductive, immune, and nervous systems, and several excellent reviews are available on these topics [107–109]. We focus here on the possible involvement of EEDs in the development of obesity and metabolic syndrome (MetS). MetS is a term for a combination of disorders that may include impaired glucose tolerance or insulin resistance, dyslipidemia, high blood pressure, and obesity [110]. Key factors are abdominal obesity and insulin resistance, where normal insulin levels are insufficient to reduce circulating levels of glucose or triglycerides.

The molecular mechanisms behind a possible involvement of EEDs, the so-called obesogens, in obesity are poorly understood. There are over one hundred chemicals, both natural and synthetic, classified as endocrine disruptors that exhibit estrogenic activity and are recognized as environmental estrogen [111–114]. The health concern over environmental estrogen is partly based on the pivotal role that natural estrogen such as E2 plays in reproduction and development. The synthetic estrogen diethylstilbestrol (DES), which was used by physicians to prevent miscarriages and in the livestock industry to enlarge poultry, cattle, and sheep [113], has become classic environmental estrogen used to model exposure in animals and humans. DES is now recognized to have led to dysfunction in reproductive organs, abnormal pregnancies, reduced fertility, immune system disorders, and depression in the daughters of women who received treatment [115]. A variety of agricultural and industrial chemicals known as organochlorines possess estrogenic activity [111, 112]. For example, o,p′-DDT an isomer of the technical grade pesticide DDT which accounts for up to 20% of the mixture [113] has been reported to be estrogenic in several species [111]. The organochlorine, polychlorinated biphenyl (PCB) which was primarily used in electrical transformers and capacitors, was reported to impair reproduction in marine mammals that fed on PCB contaminated fish [111]. Although DDT and PCBs have been banned and are not used in the United States, wildlife and humans can still be exposed due to their stability in the environment. The lipophilic property of these synthetic compounds allows them to enter the food chain as well as bioaccumulate in the adipose tissue of animals and humans. For example, a combination of environmental estrogen, such as DDT, PCBs, chlordane, and dieldrin, have been found in bald eagles [111]. In human breast milk and adipose tissue, residues of DDT, PCBs, and other organochlorine pesticides have been documented [116–119].

Evidence supporting the contribution of EEDs varies from correlative to direct induction of fat tissue. In the Faroe Islands, a study on children showed an association between prenatal dietary exposure to PCBs and DDE (a breakdown product of DDT) and increased body weight [120]. Early-life exposure to BPA was associated with increased body weight in young children [121]. Also, exposure to PCBs during fetal development or at a young age was linked with increased weight in boys and girls at puberty [122]. In support of these correlative studies, in vivo models showed that fetal exposure to either BPA or DES predisposes adult rodents to develop obesity [123, 124], while exposure to certain PCB congeners has also been shown to predispose animals to weight gain [125]. Moreover, Zanella et al. demonstrated exposure to genistein induced adipose tissue development in low fat diet mice and adipocyte proliferation in 3T3-L1 cell line [126]. Exposure to estrogenic PCB153 has also been shown to worsen HFD-induced obesity and nonalcoholic fatty liver disease (NAFLD) in mice [44]. In vitro studies on adipocyte cell lines like 3T3-L1 cell line have shown that very low concentrations of BPA increase adipocyte differentiation and lipid accumulation in a dose-dependent manner [127]. Based on these studies, prenatal exposure to EEDs may reprogram the fate of the stem cell compartment responsible for adipocyte cells, which we will describe later with respect to ID3.

7. ID3 Mediated Obesity from Exposure to EEDs

Estrogenic hormone replacement therapy has been shown to protect against many age-related changes in adipose tissue remodeling at menopause [128]. However, fetal exposure to EEDs has been demonstrated to have an opposite effect in the rodent model, which we have described previously. These effects may be in part directed by nuclear receptor signaling. BPA is a estrogenic chemical and has binding affinity for ERα and ERβ [105]. Experiments on adult mice showed that BPA acts via ERα causing an imbalance in the basal metabolic regulation of body in addition to increased fat mass [129]. Both ER signaling and synthesis of estrogen by aromatase cannot be ruled out as targets of disruption by EEDs. Our novel discovery shows that PCB153 alters the expression and activation of ID3 through ROS formation [46]. In addition, we demonstrated that the Pyk2-mediated estrogen-induced ID3 mRNA contributes to the growth of microvascular lesions [130]. ID1 which is one the members of ID proteins has been shown to interact with estrogen receptor betal (ERβ1) in breast cancer cells [131]. Moreover, it has been shown that ID1 expression is tightly regulated by E2 via ER genomic pathway in mouse uterus [132].
ID3 was shown to regulate mitochondrial function and morphology associated with changes in the expression of electron transport chain (ETC) complex components: CI (subunit NDUF88), CII (subunit SDHB), CIII (subunit UQRC2), CV (subunit ATP5A), and CIV (subunit MTCO1) [65]. Furthermore, inhibition of ID3 significantly decreased mRNA levels of mitochondrial transcription factor A (Tfam). Metabolic disorders and obesity are closely linked to higher lipid accumulation and lipogenesis. The synthesis of triglycerides (TG) is a critical step in lipogenesis process, and mitochondria facilitate the synthesis of key intermediates like glycerol 3-phosphate through the glyceroneogenic pathway and mitochondrial anaplerosis to sustain TG synthesis in the adipocyte [133]. Also, mtDNA content which is a marker for the mitochondrial number was shown to be increased significantly in white adipocytes during lipogenesis [134]. Both WAT and BAT harbor a substantial number of mitochondria [135]. Dysfunctional mitochondrial function results in increased ROS production in adipocytes and eventually results in lipid accumulation and insulin resistance [136–139]. Since ID3 is a known transcription regulator activated by PCB153, we propose that its effects on fat cell mitochondrial function may include a yet to be discovered shift in the metabolic program of adipocyte cell mitochondria. The study of the ID3 mediated mitochondrial programming holds potential promise in the prevention and treatment of obesity and metabolic disorders.

Epigenetic imprinting of adipocyte progenitor or fat stem cells by ID3 in the maternal programming of obesity shown in offspring exposed to EEDs is another plausible mechanism based on the following evidence. Specifically, we postulate that EEDs can induce ROS-mediated ID3 phosphorylation and acetylation, histone acetylation, and DNA base oxidation collectively that control expression of ID3 target genes involved in obesity and metabolic programming. This in turn controls the fate and epigenetic footprints of adipocyte progenitor cells. Reactive oxygen species like H2O2 are highly diffusible molecules. In addition to affecting ID3 signaling pathways, ROS can also facilitate histone acetylation and oxidize nuclear DNA resulting in chromatin modification. These modifications are significant because transcription in eukaryotes occurs in the context of DNA, packaged into chromatin. The basic unit of chromatin is the nucleosome, in which DNA is wrapped around the core histones H2A, H2B, H3, and H4. Acetylation of lysine in the histone tails can facilitate the opening of repressive chromatin structures in promoter regions to provide access for the transcription regulator ID3. In support of our concept that both histone acetylation and ROS-mediated DNA oxidation control the transcription of EED-induced genes, we and others have shown that E2 and PCB153-induced ROS in the nucleus, particularly H2O2, modify the surrounding DNA [49, 50, 140]. It has been recently shown that DNA oxidation through recruiting 8-oxoguanine DNA glycosylase triggers chromatin and DNA conformational changes that are essential for estrogen-mediated transcription of genes [49]. ROS generating agents and inflammation have been shown to modulate chromatin-bound histone deacetylase activity on the promoters of several genes [141–144]. Taken together, EEDs through induction of ROS may increase histone acetylations by posttranslational activation of acetylases and oxidation of DNA bases, which are necessary for ID3-mediated transcription regulation of target genes involved in obesity and metabolic complications.

Given the significant role of ID3 in stemness, it is possible that EEDs exposure may contribute to an increase in adipocyte progenitor cells. Epigenetic changes mediated by ID3 on the stem cells may ultimately increase the total number of fat cells that can be produced by an individual. Subsequent environmental exposures of these susceptible individuals who have a high number of fat stem cells, to begin with, will tend to accumulate more adipose tissue.

8. Interaction of ID3 and EEDs

In order to investigate how environmental exposures affect human health at genetic and protein level, we used Comparative Toxicogenomics Database (CTD) which is a publicly available database. CTD is a public website and research tool that consists of scientific data illustrating chemical-gene interactions and chemical-disease associations. CTD includes *in vitro* and *in vivo* data studies describing relationships between chemicals, genes, and diseases. The database manually curates information about EEDs-gene/protein interactions and EEDs-disease and gene-disease associations. We used these public databases to investigate the role of ID3, especially in various metabolic pathways. This tool can be used to decipher gene-environment or gene-EEDs interactions involved in the generation of metabolic diseases.

We initially selected specific 44 EEDs as shown in Table 1 from the list of chemicals. We then chose obesity, heart block, diabatic cardiomyopathies, idiopathic pulmonary fibrosis, hyperemia, mitochondrial complex i deficiency, aortic aneurysm, metabolic syndrome X, diabetic angiopathies, cardiomyopathy, hypertension, coronary diseases, weight gain, body weight changes, overweight, and diabetes to represent MetS. Furthermore, we checked MetS-related diseases to these 44 EEDs. We established that 664 genes are overlapping in both the MetS and EEDs list of genes. Because ID3 is our candidate gene, we created a list of genes related to ID3 and MetS-related diseases. We established that 139 genes are associated with this group. Furthermore, we found 18 common genes related to both these groups demonstrated in Figure 4 and Table 2 [145]. To show an interaction between these 18 common genes, we additionally inputted them into STRING, a database of recognized and predicted protein-protein interactions. The interactions contain direct (physical) and indirect (functional) associations which stem from computational prediction, interactions aggregated from other (primary) databases, and from knowledge transfer between organisms. As seen in Figure 5 and Table 2, STRING provides a network of these 18 common proteins and furthermore provides a pathway description for the mutually represented proteins [146]. We created Table 3 with the help of STRING network, and it shows that the involvement of the ID3 protein in the various metabolic pathway. The CTD database revealed that 18 common genes associated with MetS diseases and EEDs. Furthermore, out of these 18
### Table 1: List of estrogen endocrine disruptors (EEDs) curated through CTD (comparative Toxicogenomics Database).

| Chemical name                                      | Chemical ID | CAS RN  | Interaction count | Organism count |
|-----------------------------------------------------|-------------|---------|-------------------|----------------|
| Bisphenol A                                         | C006780     | 80-05-7 | 5                 | 3              |
| Benzo(a)pyrene                                      | D001564     | 50-32-8 | 4                 | 2              |
| Coumestrol                                           | D003375     | 479-13-0| 3                 | 1              |
| Genistein                                            | D019833     | 446-72-0| 3                 | 1              |
| Titanium dioxide                                     | C009495     | 13463-67-7| 3            | 2              |
| Cadmium chloride                                     | D019256     | 10108-64-2| 2             | 2              |
| Carbon tetrachloride                                | D002251     | 56-23-5 | 2                 | 2              |
| Dietary fats                                         | D004041     | 8016-25-9| 2                 | 1              |
| Diethylhexyl phthalate                              | D004051     | 117-81-7| 2                 | 1              |
| Diuron                                              | D004237     | 330-54-1| 2                 | 2              |
| Flutamide                                            | D005485     | 1331-84-7| 2             | 2              |
| 3,4-Dichloroaniline                                  | C014464     | 95-76-1 | 1                 | 1              |
| 4,4'-Hexafluorisopropylidene diphenol               | C583074     | 1       | 1                 | 1              |
| Aluminum                                             | D000535     | 7429-90-5| 1             | 0              |
| Amitrole                                             | D000640     | 61-82-5 | 1                 | 1              |
| Ammonium chloride                                    | D000643     | 12125-02-9| 1            | 1              |
| bis(4-Hydroxyphenyl)sulfone                          | C543008     | 80-09-1 | 1                 | 1              |
| Caffeine                                             | D002110     | 58-08-2 | 1                 | 1              |
| cobaltous chloride                                   | C018021     | 7646-79-9| 1             | 1              |
| Copper sulfate                                       | D019327     | 7758-98-7| 1             | 1              |
| Dimethoate                                           | D004117     | 60-51-5 | 1                 | 1              |
| 9,10-Dimethyl-1,2-benzanthracene                     | D015127     | 57-97-6 | 1                 | 1              |
| Formaldehyde                                         | D005557     | 50-00-0 | 1                 | 1              |
| Glycidol                                             | C004312     | 556-52-5| 1                 | 1              |
| Lead acetate                                         | C008261     | 301-04-2| 1                 | 1              |
| Lithium chloride                                     | D018021     | 7447-41-8| 1            | 1              |
| Methoxyacetic acid                                   | C013598     | 625-45-6| 1                 | 1              |
| Methoxychlor                                        | D008731     | 72-43-5 | 1                 | 1              |
| Methylcholanthrene                                   | D008748     | 56-49-5 | 1                 | 1              |
| Methylmercuric chloride                              | C004925     | 115-09-3| 1                 | 1              |
| Methylmercury Compounds                              | D008767     | 593-74-8| 1                 | 1              |
| Monobutyl phthalate                                  | C028577     | 131-70-4| 1                 | 1              |
| n-Butoxyethanol                                      | C017096     | 111-76-2| 1                 | 1              |
| Nickel sulfate                                       | C029938     | 7786-81-4| 1             | 1              |
| Nicotine                                             | D009538     | 54-11-5 | 1                 | 1              |
| Octyl methoxycinnamate                              | C18580     | 5466-77-3| 1             | 1              |
| Perfluorooctanoic acid                               | C023036     | 335-67-1| 1                 | 1              |
| Phenol                                               | D019800     | 108-95-2| 1                 | 1              |
| Polychlorinated biphenyls                            | D011078     | 59536-65-1| 1            | 1              |
| Propiconazole                                        | C045950     | 60207-90-1| 1             | 1              |
| Quercetin                                            | D011794     | 117-39-5| 1                 | 1              |
| Oxyquinoline                                         | D015125     | 148-24-3| 1                 | 1              |
| Vinclozolin                                          | C025643     | 50471-44-8| 1             | 1              |
| Zinc                                                 | D015032     | 7440-66-6| 1                 | 1              |
genes, 17 are associated with ID3. Based on these findings, we suggest there may be a molecular mechanism present between ID3/MetS-interacting genes, EED/MetS-interacting genes, and ID3/EED-interacting genes. We have summarized a potential model in Figure 6 of how EEDs-induced ROS modifies redox-sensitive ID3 protein signal transduction pathways that may contribute to the adipocytes proliferation and eventually may give rise to obesity.

9. Conclusion

ID3 has been shown to promote obesity in experimental models of HFD-induced obesity. Studies have reported associations between obesity and exposure to EEDs: BPA, DES, and PCBs. Based on the evidence discussed in this review, elevated exposure to EEDs or unopposed increase in the body burden of estrogen may increase the expression of...
in the promotion of adipogenesis by EEDs, we propose that ID3 may be an additional molecular risk factor for obesity from environmental exposure to estrogenic chemicals. Emerging evidence demonstrated that ID3 can regulate mitochondrial function and morphology associated with changes in the expression of electron transport chain complex components and TFAM. We have previously shown that ER independent mitochondrial ROS signaling contributes to the growth of cells treated with 17β-estradiol [50, 56, 147]. Therefore, ID3 mediated metabolic programming of mitochondria may be dysregulated by exposure to EEDs and increase susceptibility to obesity. In addition, the ID3 dependent production of adipocytokines and recruitment of macrophages in adipose tissue are suggested to play an important role in the inflammatory process to enhance susceptibility to obesity or metabolic complications. The potential for EEDs to influence susceptibility to obesity or metabolic disorders via ID3 dependent signaling have been summarized in Figure 6. To conclude, we have systematically reviewed the existing evidence to illustrate the association between ID3, EEDs, and obesity. Furthermore, we extended this understanding of how ID3 and metabolic perturbations by environmental factors such as EEDs can increase the risk of obesity. Research is warranted to better define the influence of EEDs and ID3 gene-environment interactions on obesity. A better understanding of how ID3 and EEDs affect the risk

![Figure 6: Summarization of ID3 interaction with EEDs, which may contribute to obesity.](image)

| Table 2 | ID3, MetS related diseases & EEDs genes |
|---------|----------------------------------------|
| APOE    |                                       |
| ATF3    |                                       |
| BMPR2   |                                       |
| GPX3    |                                       |
| ID1     |                                       |
| ID3     |                                       |
| ID4     |                                       |
| IGF1    |                                       |
| MKD     |                                       |
| MEST    |                                       |
| MFG8    |                                       |
| MMP14   |                                       |
| MMP3    |                                       |
| NKX2-5  |                                       |
| SREBI1  |                                       |
| ST6GAL1 |                                       |
| THBS1   |                                       |
| VEGFA   |                                       |

the transcription regulator ID3. Although we cannot rule out the contribution of ER signaling and aromatase activity
| Pathway ID     | Pathway description                                      | Matching proteins in your network (labels)                                                                 |
|---------------|----------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| GO.0000944    | Vascular development                                     | APOE, BMPR2, ID1, IGF1, MFGE8, MMP14, NKK2-5, THBS1, VEGFA                                               |
| GO.0072358    | Cardiovascular system development                        | APOE, BMPR2, ID1, ID3, IGF1, MFGE8, MMP14, NKK2-5, THBS1, VEGFA                                          |
| GO.0072359    | Circulatory system development                           | APOE, BMPR2, ID1, ID3, IGF1, MFGE8, MMP14, NKK2-5, THBS1, VEGFA                                          |
| GO.0000568    | Blood vessel development                                 | APOE, BMPR2, ID1, MFGE8, MMP14, NKK2-5, THBS1, VEGFA                                                   |
| GO.0030324    | Lung development                                         | BMPR2, ID1, IGF1, MMP4, SREBF1, VEGFA                                                                   |
| GO.0048514    | Blood vessel morphogenesis                               | APOE, ID1, MFGE8, MMP14, NKK2-5, THBS1, VEGFA                                                          |
| GO.0080941    | Regulation of cell death                                 | APOE, ATF3, ID1, ID3, IGF1, MDK, MMP3, NKK2-5, THBS1, VEGFA                                            |
| GO.0050678    | Regulation of epithelial cell proliferation              | APOE, BMPR2, ID1, IGF1, THBS1, VEGFA                                                                   |
| GO.0048511    | Rhythmic process                                         | ID1, ID3, ID4, MMP14, SREBF1, VEGFA                                                                    |
| GO.0030334    | Regulation of cell migration                             | APOE, BMPR2, IGF1, MFGE8, MMP3, THBS1, VEGFA                                                           |
| GO.000525     | Angiogenesis                                             | ID1, MFGE8, MMP14, THBS1, VEGFA                                                                        |
| GO.0007623    | Circadian rhythm                                         | ID1, ID3, ID4, SREBF1                                                                                   |
| GO.0006979    | Response to oxidative stress                             | APOE, GPX3, MMP14, MMP3, THBS1                                                                        |
| GO.000302     | Response to reactive oxygen species                      | APOE, GPX3, MMP3, THBS1                                                                                |
| GO.0031325    | Positive regulation of cellular metabolic process        | APOE, ATF3, BMPR2, ID4, IGF1, MDK, MMP14, NKK2-5, THBS1, VEGFA                                         |
| GO.0048545    | Response to steroid hormone                              | MDK, MFGE8, MMP14, SREBF1, THBS1                                                                       |
| GO.0031324    | Negative regulation of cellular metabolic process        | APOE, BMPR2, ID1, IGF1, MMP3, NKK2-5, SREBF1, THBS1, VEGFA                                            |
| GO.0045450    | Regulation of cholesterol biosynthetic process           | APOE, SREBF1                                                                                            |
| GO.0006950    | Response to stress                                       | APOE, BMPR2, GPX3, ID3, IGF1, MMP14, MMP3, SREBF1, THBS1, VEGFA                                       |
| GO.000935     | Endothelial cell proliferation                           | BMPR2, MMP14                                                                                           |
| GO.0008283    | Cell proliferation                                       | BMPR2, ID4, IGF1, MMP4, NKK2-5                                                                         |
| GO.004334     | Positive regulation of blood vessel endothelial cell migration | THBS1, VEGFA                                                |
| GO.005145     | Cellular macromolecule biosynthetic process              | APOE, ATF3, BMPR2, ID1, ID3, ID4, IGF1, SREBF1, ST6GAL1, THBS1                                        |
| GO.005178     | Positive regulation of cell division                     | IGF1, MDK, VEGFA                                                                                       |
| GO.0009101    | Glycoprotein biosynthetic process                        | BMPR2, IGF1, ST6GAL1, THBS1                                                                           |
| GO.0008861    | Regulation of cell size                                  | APOE, BMPR2, VEGFA                                                                                     |
| GO.0043534    | Blood vessel endothelial cell migration                  | ID1, VEGFA                                                                                            |
| GO.0016477    | Cell migration                                           | ID1, MDK, MMP14, THBS1, VEGFA                                                                          |
| GO.0032369    | Negative regulation of lipid transport                   | APOE, THBS1                                                                                            |
| GO.0048568    | Embryonic organ development                              | ID3, MMP14, NKK2-5, VEGFA                                                                             |
| GO.0045765    | Regulation of angiogenesis                               | ID1, THBS1, VEGFA                                                                                      |
| GO.005172     | Negative regulation of nitrogen compound metabolic process | APOE, BMPR2, ID1, NKK2-5, SREBF1, VEGFA                                                             |
| GO.0007166    | Cell surface receptor signaling pathway                  | BMPR2, ID1, IGF1, MDK, NKK2-5, SREBF1, VEGFA                                                          |
| GO.0032269    | Negative regulation of cellular protein metabolic process | APOE, ATF3, IGF1, THBS1, VEGFA                                                                   |
| GO.0045937    | Positive regulation of phosphate metabolic process       | APOE, BMPR2, IGF1, THBS1, VEGFA                                                                      |
| GO.0051148    | Negative regulation of muscle cell differentiation       | ID3, NKK2-5                                                                                           |
| GO.0030135    | Regulation of cell adhesion                              | IGF1, MMP14, THBS1, VEGFA                                                                              |
of obesity may open up new avenues for prevention and treatment of diseases that metabolic syndrome manifest.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] L. A. Barness, J. M. Opitz, and E. Gilbert-Barness, “Obesity: genetic, molecular, and environmental aspects,” *American Journal of Medical Genetics Part A*, vol. 143, no. 24, pp. 3016–3034, 2007.

[2] S. A. Ritchie and J. M. Connell, “The link between abdominal obesity, metabolic syndrome and cardiovascular disease,” *Nutrition, Metabolism & Cardiovascular Diseases*, vol. 17, no. 4, pp. 319–326, 2007.

[3] S. Collins, “Overview of clinical perspectives and mechanisms of obesity,” *Birth Defects Research Part A - Clinical and Molecular Teratology*, vol. 73, no. 7, pp. 470–471, 2005.

[4] A. H. Mokdad, M. K. Serdula, W. H. Dietz, B. A. Bowman, J. S. Marks, and J. P. Koplan, “The spread of the obesity epidemic in the United States, 1991–1998,” *Journal of the American Medical Association*, vol. 282, no. 16, pp. 1519–1522, 1999.

[5] A. H. Mokdad, E. S. Ford, B. A. Bowman et al., “Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001,” *The Journal of the American Medical Association*, vol. 289, no. 1, pp. 76–79, 2003.

[6] WHO — Obesity and overweight, WHO, 2017, http://www.who.int/mediacentre/factsheets/fs311/en/.

[7] J. Cawley and C. Meyerhoefer, “The medical care costs of obesity: an instrumental variables approach,” *Journal of Health Economics*, vol. 31, no. 1, pp. 219–230, 2012.

[8] L. Trasande, R. T. Zoeller, U. Hass et al., “Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 100, no. 4, pp. 1245–1255, 2015.

[9] A. Tchernof and J.-P. Després, “Pathophysiology of human visceral obesity: an update,” *Physiological Reviews*, vol. 93, no. 1, pp. 359–404, 2013.

[10] C. Bélanger, V. Liu-The, P. Dupont, and A. Tchernof, “Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity,” *Hormone and Metabolic Research*, vol. 34, no. 11–12, pp. 737–745, 2002.

[11] A. Meseguer, C. Puche, and A. Cabero, “Sex steroid biosynthesis in white adipose tissue,” *Hormone and Metabolic Research*, vol. 34, no. 11-12, pp. 731–736, 2002.

[12] P. C. MacDonald, C. D. Edman, D. L. Hemsell, J. C. Porter, and P. K. Siiteri, “Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer,” *American Journal of Obstetrics & Gynecology*, vol. 130, no. 4, pp. 448–455, 1978.

[13] D. L. Hemsell, J. M. Grodin, P. F. Brenner, P. K. Siiteri, and P. C. MacDonald, “Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 38, no. 3, pp. 476–479, 1974.

[14] P. C. MacDonald, J. D. Madden, P. F. Brenner, J. D. Wilson, and P. K. Siiteri, “Origin of estrogen in normal men and in women with testicular feminization,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 49, no. 6, pp. 905–916, 1979.

[15] J. M. Grodin, P. K. Siiteri, and P. C. MacDonald, “Source of estrogen production in postmenopausal women,” *Obstetrics & Gynecological Survey*, vol. 28, no. 9, pp. 654–655, 1973.

[16] K. E. Davis, M. D. Neinast, and K. Sun, “The sexually dimorphic role of adipose and adipocyteline receptors in modulating adipose tissue expansion, inflammation, and fibrosis,” *Molecular Metabolism*, vol. 2, no. 3, pp. 227–242, 2013.

[17] B. G. Drew, H. Hamidi, Z. Zhou et al., “Estrogen receptor (erα)-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression,” *The Journal of Biological Chemistry*, vol. 290, no. 9, pp. 5566–5581, 2015.

[18] E. K. Shanle and W. Xu, “Selectively targeting estrogen receptors for cancer treatment,” *Advanced Drug Delivery Reviews*, vol. 62, no. 13, pp. 1265–1276, 2010.

[19] N. Heldring, A. Pike, S. Andersson et al., “Estrogen receptors: How do they signal and what are their targets?,” *Physiological Reviews*, vol. 87, no. 3, pp. 905–931, 2007.

[20] C. D. Toran-Allerand, X. Guan, N. J. MacLusky et al., “ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury,” *The Journal of Neuroscience*, vol. 22, no. 19, pp. 8391–8401, 2002.

[21] J. Qiu, M. A. Bosch, S. C. Tobias et al., “Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C,” *Journal of Neuroscience*, vol. 23, no. 29, pp. 9529–9540, 2003.

[22] A. H. Largrange, O. K. Ronnkleiev, and M. J. Kelly, “Modulation of G protein-coupled receptors by an estrogen receptor that activates protein kinase A,” *Molecular Pharmacology*, vol. 51, no. 4, pp. 605–612, 1997.

[23] E. J. Filardo, J. A. Quinn, K. I. Bland, and A. R. Frackelton Jr., “Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-IGF,” *Molecular Endocrinology*, vol. 14, no. 10, pp. 1649–1660, 2000.

[24] G. Bondar, J. Kuo, N. Hamid, and P. Micevych, “Estradiol-induced estrogen receptor-α trafficking,” *The Journal of Neuroscience*, vol. 29, no. 48, pp. 15323–15330, 2009.

[25] S. V. Gorosito, A. G. Lorenzo, and M. J. Cambiasso, “Estrogen receptor α is expressed on the cell-surface of embryonic hypothalamic neurons,” *Neuroscience*, vol. 154, no. 4, pp. 1173–1177, 2008.

[26] J. K. Skipper, L. J. Young, J. M. Bergeron, M. T. Tetzlaff, C. T. Osborn, and D. Crews, “Identification of an isoform of the estrogen receptor messenger RNA lacking exon four and present in the brain,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 90, no. 15, pp. 7172–7175, 1993.

[27] A. Nadal, A. B. Ropero, O. Laribi, M. Maillet, E. Fuentes, and B. Soria, “Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor α and estrogen receptor β,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 21, pp. 11603–11608, 2000.

[28] C. S. Watson, N. N. Bulayeva, A. L. Wozniak, and C. C. Finnerty, “Signaling from the membrane via membrane estrogen receptor-α: Estrogens, xenoestrogens, and phytoestrogens,” *Steroids*, vol. 70, no. 5–7, pp. 364–371, 2005.
[29] P. Thomas and J. Dong, “Binding and activation of the seven-transmembrane estrogen receptor GP380 by environmental estrogens: a potential novel mechanism of endocrine disruption,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 102, no. 1–5, pp. 175–179, 2006.

[30] K. S. Korach, P. Sarver, K. Chae, J. A. McLachlan, and J. D. McKinney, “Estrogen receptor-binding activity of polychlorinated hydroxybiphenyls: Conformationally restricted structural probes,” Molecular Pharmacology, vol. 33, no. 1, pp. 120–126, 1988.

[31] E. C. Bonefeld-Jorgensen, H. R. Andersen, T. H. Rasmussen, and A. M. Vinggaard, “Effect of highly bioaccumulated polychlorinated biphenyl congeners on estrogen and androgen receptor activity,” Toxicology, vol. 158, no. 3, pp. 141–153, 2001.

[32] E. Diamanti-Kandarakis, J. P. Bourguignon, L. C. Giudice et al., “Endocrine-disrupting chemicals: an Endocrine Society scientific statement,” Endocrine Reviews, vol. 30, no. 4, pp. 293–342, 2009.

[33] A. Zsarnovszky, H. H. Le, H.-S. Wang, and S. M. Belcher, “Ontogeny of rapid estrogen-mediated extracellular signal-regulated kinase signaling in the rat cerebellar cortex: Potent nongenomic agonist and endocrine disrupting activity of the xenoestrogen bisphenol A,” Endocrinology, vol. 146, no. 12, pp. 5388–5396, 2005.

[34] G. Rasier, A.-S. Parent, A. Géraud, M.-C. Lebrethon, and J.-P. Bourguignon, “Early maturation of gonadotropin-releasing hormone secretion and sexual precocity after exposure of infant female rats to estradiol or dichlorodiphenyltrichloroethane,” Biology of Reproduction, vol. 77, no. 4, pp. 734–742, 2007.

[35] E. T. Jensen and M. P. Longnecker, “Pharmacologic sex hormones in pregnancy in relation to offspring obesity,” Obesity, vol. 22, no. 11, pp. 2406–2414, 2014.

[36] R. R. Newbold, E. Padilla-Banks, and W. N. Jefferson, “Environmental estrogens and obesity,” Molecular and Cellular Endocrinology, vol. 304, no. 1-2, pp. 84–89, 2009.

[37] Z. Zebedee and E. Hara, “Id proteins in cell cycle control and cellular senescence,” Oncogene, vol. 20, no. 58, pp. 8317–8325, 2001.

[38] A. Lasorella, R. Benezra, and A. Iavarone, “The ID proteins: Master regulators of cancer stem cells and tumour aggressiveness,” Nature Reviews Cancer, vol. 14, no. 2, pp. 77–91, 2014.

[39] R. Benezra, R. L. Davis, D. Lockshon, D. L. Turner, and H. Weintraub, “The protein Id: a negative regulator of helix-loop-helix DNA binding proteins,” Cell, vol. 61, no. 1, pp. 49–59, 1990.

[40] M. Duncan, E. M. DiCicco-Bloom, X. Xiang, R. Benezra, and K. Chada, “The gene for the helix-loop-helix protein, Id, is specifically expressed in neural precursors,” Developmental Biology, vol. 154, no. 1, pp. 1–10, 1992.

[41] W. Ellmeier and A. Weith, “Expression of the helix-loop-helix DNA binding proteins,” Developmental Dynamics, vol. 203, no. 2, pp. 163–173, 1995.

[42] Y. Jen, K. Manova, and R. Benezra, “Each member of the Id gene family exhibits a unique expression pattern in mouse gut development and neurogenesis,” Developmental Dynamics, vol. 208, no. 1, pp. 92–106, 1997.

[43] D. Lyden, A. Z. Young, D. Zagzag et al., “Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts,” Nature, vol. 401, no. 6754, pp. 670–677, 1999.

[44] B. Wahlang, K. C. Falkner, B. Gregory et al., “Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens nonalcoholic fatty liver disease in male C57BL/6J mice,” The Journal of Nutritional Biochemistry, vol. 24, no. 9, pp. 1587–1595, 2013.

[45] D. Mullerova, J. Kopecky, D. Matejkova et al., “Negative association between plasma levels of adiponectin and polychlorinated biphenyl 153 in obese women under non-energy-restrictive regime,” International Journal of Obesity, vol. 32, no. 12, pp. 1875–1878, 2008.

[46] J. K. Das and Q. Falty, “PCB53-induced overexpression of ID3 contributes to the development of microvascular lesions,” PLoS ONE, vol. 9, no. 8, Article ID e104159, 2014.

[47] C. Mueller, S. Baudler, H. Welzel, M. Böhm, and G. Nickenig, “Identification of a novel redox-sensitive gene, Id3, which mediates Angiotensin II-induced cell growth,” Circulation, vol. 105, no. 20, pp. 2423–2428, 2002.

[48] Q. Falty and N. Porthier, “Estrogen-induced redox sensitive Id3 signaling controls the growth of vascular cells,” Atherosclerosis, vol. 198, no. 1, pp. 12–21, 2008.

[49] B. Perillo, M. N. Ombara, A. Bertoni et al., “DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression,” Science, vol. 319, no. 5860, pp. 202–206, 2008.

[50] J. Parkash, Q. Falty, and D. Roy, “Estrogen exerts a spatial and temporal influence on reactive oxygen species generation that precedes calcium uptake in high-capacity mitochondria: Implications for rapid nongenomic signaling of cell growth,” Biochemistry, vol. 45, no. 9, pp. 2872–2881, 2006.

[51] V. O. Okoh, Q. Falty, J. Parkash, R. Popitti, and D. Roy, “Reactive Oxygen Species via Redox Signaling to PI3K/PAK Pathway Contribute to the Malignant Growth of 4-Hydroxy Estradiol-Transformed Mammary Epithelial Cells,” PLoS ONE, vol. 8, no. 2, Article ID e54206, 2013.

[52] P. Rajesh, S. Sathish, C. Srinivasan, J. Selvaraj, and K. Balasubramanian, “Diethyl Hexyl Pthalate (DEHP) is associated with insulin resistance in adipose tissue of male rat: Protective role of antioxidant vitamins (C & E),” Journal of Cellular Biochemistry, vol. 114, no. 3, pp. 558–569, 2013.

[53] D. Tiwari, J. Kambie, S. Chiligunde et al., “Clastogenic and mutagenic effects of bisphenol A: an endocrine disruptor,” Mutation Research - Genetic Toxicology and Environmental Mutagenesis, vol. 743, no. 1-2, pp. 83–90, 2012.

[54] M. L. Bustos, L. Huleihel, M. G. Kapetanaki et al., “Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response,” American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 7, pp. 787–798, 2014.

[55] W. Wang, Y. Zhang, W. Lu, and K. Liu, “Mitochondrial reactive oxygen species regulate adipocyte differentiation of mesenchymal stem cells in hematopoietic stress induced by arabinosycytosine,” PLoS ONE, vol. 10, no. 3, article e0120629, 2015.

[56] Q. Falty, W.-C. Xiong, D. Sun et al., “Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers,” Biochemistry, vol. 44, no. 18, pp. 6900–6909, 2005.

[57] P. Monje and R. Boland, “Subcellular distribution of native estrogen receptor α and β isoforms in rabbit uterus and ovary,” Journal of Cellular Biochemistry, vol. 82, no. 3, pp. 467–479, 2001.

[58] J. Q. Chen, M. Delannoy, C. Cooke, and J. D. Yager, “Mitochondrial localization of ER and ER in human MCF7 cells,” American Journal of Physiology-Renal Physiology, vol. 286, no. 6, pp. E1011–E1022, 2004.

[59] J. Q. Chen, M. Esthe, W. L. Alworth, and J. D. Yager, “Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors α and β to human mitochondrial DNA estrogen response elements,” Journal of Cellular Biochemistry, vol. 93, no. 2, pp. 358–373, 2004.
A. M. Taylor, F. Li, P. Thimmalapura et al., “Hyperlipemia and...

J. L. Kaplan, M. A. Marshall, C. C. McSkimming et al.,...

J. K. Das, N. F. Voelkel, and Q. Felty, “ID3 contributes...

A. Lazorchak, M. E. Jones, and Y. Zhuang, “New insights...

J. L. Kaplan, M. A. Marshall, C. C. McSkimming et al.,...

M. Moldes, F. Lasnier, B. Fève, J. Pairault, and P. Djian, “Id3...

B. M. Spiegelman and J. S. Flier, “Adipogenesis and obesity:

A. Cutchins, D. B. Harmon, J. L. Kirby et al., “Inhibitor of...

C. Murre, P. S. McCaw, and D. Baltimore, “A new DNA binding...

L. B. Sales, J. H. Kamstra, P. H. Cenijn, L. S. van Rijt, T. Hamers, J. C. Murre, P. S. McCaw, and D. Baltimore, “A new DNA binding motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins,” Cell, vol. 56, no. 5, pp. 777–783, 1989.

A. Lazorchak, M. E. Jones, and Y. Zhuang, “New insights into E-protein function in lymphocyte development,” Trends in Immunology, vol. 26, no. 6, pp. 334–338, 2005.

X.-H. Sun, “Multitasking of helix-loop-helix proteins in lymphopoiesis,” Advances in Immunology, vol. 84, pp. 43–77, 2004.

A. M. Taylor, F. Li, P. Thimmalapura et al., “Hyperlipemia and oxidation of LDL induce vascular smooth muscle cell growth: An effect mediated by the HLH factor Id3,” Journal of Vascular Research, vol. 43, no. 2, pp. 123–130, 2006.

M. Bensellam, M. K. Montgomerie, J. Luzuriaga, J. Y. Chan, and D. R. Laybutt, “Inhibitor of differentiation proteins protect against oxidative stress by regulating the antioxidant–mitochondrial response in mouse beta cells,” Diabetologia, vol. 58, no. 4, pp. 758–770, 2015.

J. K. Das, N. F. Voelkel, and Q. Felty, “Id3 contributes to the acquisition of molecular stem cell-like signature in microvascular endothelial cells: Its implication for understanding microvascular diseases,” Microvascular Research, vol. 98, pp. 126–138, 2015.

M. Manikkam, R. Tracey, C. Guerrero-Bosagna, and M. K. Skinner, “Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations,” PLoS ONE, vol. 8, no. 1, Article ID e55387, 2013.

Q. Wu, Z.-J. Zhou, and S. Ohsako, “Effect of environmental contaminants on DNA methyltransferase activity of mouse preimplantation embryos,” Wei Sheng Yan Jiu, vol. 35, no. 1, pp. 30–32, 2006.

L. B. Sales, J. H. Kamstra, P. H. Cenijn, L. S. van Rijt, T. Hamers, and J. Legler, “Effects of endocrine disrupting chemicals on in vitro global DNA methylation and adipocyte differentiation,” Toxicology in Vitro, vol. 27, no. 6, pp. 1634–1643, 2013.

A. E. Knowell, D. Patel, D. J. Morton, P. Sharma, S. Glymph, and J. Chaudhary, “Id4 dependent acetylation restores mutant-p53 transcriptional activity,” Molecular Cancer, vol. 12, no. 1, article no. 161, 2013.

L. Aloia, A. Gutierrez, J. M. Caballero, and L. Di Croce, “Direct interaction between Id1 and Zrf1 controls neuronal differentiation of embryonic stem cells,” EMBO Reports, vol. 16, no. 1, pp. 63–70, 2015.

M. Moldes, F. Lasnier, B. Fève, J. Parenta, and P. Dijan, “Id3 prevents differentiation of preadipose cells,” Molecular and Cellular Biology, vol. 17, no. 4, pp. 1796–1804, 1997.

S. Klaus, “Functional differentiation of white and brown adipocytes,” BioEssays, vol. 19, no. 3, pp. 215–223, 1997.

B. M. Spiegelman and J. S. Flier, “Adipogenesis and obesity: Rounding out the big picture,” Cell, vol. 87, no. 3, pp. 377–389, 1996.

A. Cutchins, D. B. Harmon, J. L. Kirby et al., “Inhibitor of differentiation-3 mediates high fat diet-induced visceral fat expansion,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 2, pp. 317–324, 2012.
[91] E. Zoico, U. Garbin, D. Olioso et al., “The effects of adiponectin on interleukin-6 and MCP-1 secretion in lipopolysaccharide-treated 3T3-L1 adipocytes: Role of the NF-κB pathway,” *International Journal of Molecular Medicine*, vol. 24, no. 6, pp. 847–851, 2009.

[92] N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” *Nature Reviews Immunology*, vol. 11, no. 2, pp. 85–97, 2011.

[93] J. S. Mayes and G. H. Watson, “Direct effects of sex steroid hormones on adipose tissues and obesity,” *Obesity Reviews*, vol. 5, no. 4, pp. 197–216, 2004.

[94] C. Ohlsson, N. Hellberg, P. Parini et al., “Obesity and disturbed lipoprotein profile in estrogen receptor-α-deficient male mice,” *Biochemical and Biophysical Research Communications*, vol. 348, no. 1, p. 326, 2006.

[95] A. Anwar, P. G. McTernan, L. A. Anderson et al., “Site-specific regulation of oestrogen receptor-α and -β by oestradiol in human adipose tissue,” *Diabetes, Obesity and Metabolism*, vol. 3, no. 5, pp. 338–349, 2001.

[96] M. N. Dieudonné, M. C. Leneveu, Y. Giudicelli, and R. Pecquery, “Evidence for functional estrogen receptors α and β in human adipose cells: regional specificities and regulation by estrogens,” *American Journal of Physiology-Cell Physiology*, vol. 286, no. 3, pp. C655–C661, 2004.

[97] L. R. Nelson and S. E. Bulun, “Estrogen production and action,” *Journal of the American Academy of Dermatology*, vol. 45, no. 3, pp. S116–S124, 2001.

[98] J. C. Lovejoy, “The menopause and obesity,” *Primary Care—Clinics in Office Practice*, vol. 30, no. 2, pp. 317–325, 2003.

[99] S. M. Al-Qahtani, G. Bryzgalova, I. Valladolid-Acebes et al., “17β-Estradiol suppresses visceral adipogenesis and activates brown adipose tissue-specific gene expression,” *Hormone Molecular Biology and Clinical Investigation*, vol. 29, no. 1, pp. 13–26, 2017.

[100] J. Laitinen, C. Power, and M.-R. Jarvelin, “Family social class, maternal body mass index, childhood body mass index, and age at menarche as predictors of adult obesity,” *American Journal of Clinical Nutrition*, vol. 74, no. 3, pp. 287–294, 2001.

[101] F. M. Biro, R. P. McMahon, R. Striegel-Moore et al., “Impact of timing of pubertal maturation on growth in black and white female adolescents: The National Heart, Lung, and Blood Institute Growth and Health Study,” *Journal of Pediatrics*, vol. 138, no. 5, pp. 636–643, 2001.

[102] E. P. M. Kruijver, R. Balesar, A. M. Espila, U. A. Unmehopa, and D. F. Swaab, “Estrogen receptor-α distribution in the human hypothalamus in relation to sex and endocrine status,” *Journal of Comparative Neurology*, vol. 454, no. 2, pp. 115–139, 2002.

[103] M. E. Couce, B. Burguera, J. E. Parisi, M. D. Jensen, and R. V. Lloyd, “Localization of leptin receptor in the human brain,” *Neuroendocrinology*, vol. 66, no. 3, pp. 145–150, 1997.

[104] M. E. E. Jones, A. W. Thorburn, K. L. Britt et al., “Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 23, pp. 12735–12740, 2000.

[105] G. J. M. Kuiper, J. G. Lemmen, B. Carlsson et al., “Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β,” *Endocrinology*, vol. 139, no. 10, pp. 4252–4263, 1998.

[106] K. W. Gaido, S. C. Maness, D. P. McDonnell, S. S. Dehal, D. Kupfer, and S. Safe, “Interaction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies,” *Molecular Pharmacology*, vol. 58, no. 4, pp. 852–858, 2000.

[107] D. W. Singleton and S. A. Khan, “Xenoestrogen exposure and mechanisms of endocrine disruption,” *Frontiers in Bioscience*, vol. 8, pp. s110–s118, 2003.

[108] M. M. Tabban and D. Bluemberg, “New modes of action for endocrine-disrupting chemicals,” *Molecular Endocrinology*, vol. 20, no. 3, pp. 475–482, 2006.

[109] G. C. Panzica, C. Viglietti-Panzica, and M. A. Ottinger, “Introduction: Neurobiological impact of environmental estrogens,” *Brain Research Bulletin*, vol. 65, no. 3, pp. 187–191, 2005.

[110] J.-P. Després, I. Lemieux, and J. Bergeron, “Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 6, pp. 1039–1049, 2008.

[111] J. Bitman and H. C. Cecili, “Estrogenic activity of DDT analogs and polychlorinated biphenyls,” *Journal of Agricultural and Food Chemistry*, vol. 18, no. 6, pp. 1108–1112, 1970.

[112] J. A. Nelson, R. F. Struck, and R. James, “Estrogenic activities of chlorinated hydrocarbons,” *Journal of Toxicology and Environmental Health*, vol. 4, no. 2–3, pp. 325–339, 1978.

[113] J. Mclachlan, “Diethylstilbestrol and other estrogens in the environment*1*,” *Fundamental and Applied Toxicology*, vol. 4, no. 5, pp. 686–691, 1984.

[114] D. Roy, J. B. Colerangle, and K. P. Singh, “Is exposure to environmental or industrial endocrine disrupting estrogen-like chemicals able to cause genomic instability?” *Frontiers in Bioscience*, vol. 3, no. 4, pp. d913–d921, 1998.

[115] J. Laitman, “DES exposure and the aging woman: mothers and daughters,” *Current Women’s Health Reports*, vol. 2, no. 5, p. 390, 2002.

[116] A. Polder, J. O. Odland, A. Tkachev, S. Føreid, T. N. Savinova, and J. U. Skaare, “Geographic variation of chlorinated pesticides, toxaphenes and PCBs in human milk from sub-arctic and arctic locations in Russia,” *Science of the Total Environment*, vol. 306, no. 1–3, pp. 179–195, 2003.

[117] H.-R. Chao, S.-L. Wang, T.-C. Lin, and X.-H. Chung, “Levels of organochlorine pesticides in human milk from central Taiwan,” *Chemosphere*, vol. 62, no. 11, pp. 1774–1785, 2006.

[118] E. R. Burke, A. J. Holden, and I. C. Shaw, “A method to determine residue levels of persistent organochlorine pesticides in human milk from Indonesian women,” *Chemosphere*, vol. 50, no. 4, pp. 529–535, 2003.

[119] A. Azeredo, J. P. M. Torres, M. de Freitas Fonseca et al., “DDT and its metabolites in breast milk from the Madeira River basin in the Amazon, Brazil,” *Chemosphere*, vol. 73, no. 1, pp. S246–S251, 2008.

[120] J. L. Tang-Pérondin, B. L. Heimann, H. R. Andersen et al., “Association between prenatal polychlorinated biphenyl exposure and obesity development at ages 5 and 7 y: a prospective cohort study of 656 children from the Faroe Islands,” *American Journal of Clinical Nutrition*, vol. 99, no. 1, pp. 5–13, 2014.

[121] M. Vafeiadi, T. Roumeliotaki, A. Myridakis et al., “Association of early life exposure to bisphenol A with obesity and cardiometabolic traits in childhood,” *Environmental Research*, vol. 146, pp. 379–387, 2016.

[122] R. W. Stahlhut, E. van Wijngaarden, T. D. Dye, S. Cook, and S. H. Swan, “Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males,” *Environmental Health Perspectives*, vol. 115, no. 6, pp. 876–882, 2007.
insulin resistance in both rodents and humans,” The Journal of Clinical Investigation, vol. 119, no. 3, pp. 573–581, 2009.

[138] K. V. Tormos, E. Anso, R. B. Hamanaka et al., “Mitochondrial complex III ROS regulate adipocyte differentiation,” Cell Metabolism, vol. 14, no. 4, pp. 537–544, 2011.

[139] J. M. Curtis, P. A. Grimsrud, W. S. Wright et al., “Downregulation of adipose glutathione S-transferase A4 leads to increased protein carbonylation, oxidative stress, and mitochondrial dysfunction,” Diabetes, vol. 59, no. 5, pp. 1132–1142, 2010.

[140] V. Okoh, A. Deoraj, and D. Roy, “Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1815, no. 1, pp. I15–I13, 2011.

[141] F. M. Moodie, J. A. Marwick, C. S. Anderson et al., “Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kB activation and proinflammatory cytokine release in alveolar epithelial cells,” The FASEB Journal, vol. 18, no. 15, pp. 1897–1899, 2004.

[142] I. M. Adcock, B. Cosio, L. Tsaprouni, P. J. Barnes, and K. Ito, “Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response,” Antioxidants & Redox Signaling, vol. 7, no. 1-2, pp. 144–152, 2005.

[143] N. Pediconi, F. Guerrieri, S. Vossio et al., “hSirT1-Dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage,” Molecular and Cellular Biology, vol. 29, no. 8, pp. 1989–1998, 2009.

[144] A. Brunet, L. B. Sweeney, J. F. Sturgill et al., “Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase,” Science, vol. 303, no. 5666, pp. 2011–2015, 2004.

[145] A. P. Davis, C. J. Grondin, R. J. Johnson et al., “The Comparative Toxicogenomics Database: Update 2017,” Nucleic Acids Research, vol. 45, no. 1, pp. D972–D978, 2017.

[146] D. Szkarczyk, A. Franceschini, S. Wyder et al., “STRING v10: protein-protein interaction networks, integrated over the tree of life,” Nucleic Acids Research, vol. 43, pp. D447–D452, 2015.

[147] Q. Feltz and D. Roy, “Estrogen, mitochondria, and growth of cancer and non-cancer cells,” Journal of Carcinogenesis, vol. 4, no. 1, p. 1, 2005.